Cambrian Biopharma – Juliette Han Q&A

Latest articles

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

The Alliance for Longevity Initiatives – fighting aging

Advancing legislation and policies that aim to increase healthy human lifespan. Longevity is a journey that would be good to imagine we're all taking together;...

Team builds first living robots – that can reproduce

AI-designed Xenobots reveal entirely new form of biological self-replication which could prove promising for regenerative medicine. Birds do it, bees do it... now even living...

Aging in place trailblazer focus – Carewell

Carewell – aiding individuals through their caregiving journey with empathy and knowledge. Over the coming weeks, we will be bringing you extracts from 7 trailblazer...

Click the globe for translations.

Longevity biotech exclusive Q&A with Cambrian Biopharma’s Chief Operating Officer.

Recently we reported on Cambrian Biopharma, a New York-based biotech which raised $60 million to develop a pipeline of companies and therapeutics to treat diseases of aging. This exciting development piqued our interest, and the Cambrian triumvirate of James Peyer, CEO and Co-Founder, Juliette Han, COO and Daisy Robinton, Scientist in Residence were kind enough to answer our questions.

Longevity.Technology: Cambrian made a splash when they emerged from stealth, and we were intrigued by their unique operational strategy, which is called DisCo (this is D, delightful; I, irresistible), and stands for distributed drug discovery company. Working as a hub-and-spoke model, Cambrian hopes to develop a family of companies; it is the largest shareholder in one of its affiliate companies, Sensei Bio, which raised $133m when it began trading last month.

First out of the gate, Dr Juliette Han holds a PhD in Neuroscience from Harvard University and is Cambrian’s Chief Operating Officer.

“We’re figuring out a way to make the drug discovery process more thoughtfully and flexibly resourced and programmatic, to increase its overall chance of success,” she says of Cambrian‘s mission. “Our sweet spot is finding scientists with promising druggable targets that align with our mandate, and we provide the drug discovery and operational expertise.”

The Cambrian support model as a logical approach – almost Henry Ford-like. Does Dr Han feel it has a synergistic benefit, development-wise?”

“I would like to liken our model to that of a top Michelin star restaurant vs the Henry Ford assembly line,” says Dr Han. “Such restaurants are able to assemble a diverse team each of whom is a top tier expert in his/her role – the sommelier, the chef, the server, the maître d, the mixologist, etc. This team is expected to deliver at the level of excellence one would expect of such a restaurant for every meal, every day. In addition, the team needs to deliver with consistency under constantly fluctuating conditions, ranging from changing market trends, resources, competition, and even regulatory.

 


 

“I would like to liken our model to that of a top Michelin star restaurant vs the Henry Ford assembly line”

 


 

“This is how our team is designed to operate. We are building a core team comprised of venture, R&D, and operations, pulling in additional experts for each workstream/content area. The team is expected to leverage their expertise to adapt and customize its approach for each of our programs, but to deliver consistently regardless of what new challenges they face. This A team is able to flexibly deploy based on the needs of the program, pulling in the right expertise to meet that next milestone. In this way, it absolutely has synergistic benefit: even our earliest stage programs are able to get input from the best experts they may not have had access to alone.

“In addition, our teams come together centrally to share best practices and quickly pivot their approach as needed. This way, our programs are gaining the experience and knowledge of not only the experts aligned to their program, but also those broadly within Cambrian’s team and network.”

75 to 80% of drug trials fail are due to problems with efficacy and/or safety; is Dr Han hoping for a higher success rate at Cambrian?

“The success rate we compare our programs to will depend both on the indications our programs go after, and improvement in the probability of success data in the industry,” she says. “As for indication, as long as the program meets our investment mandate of impact on longevity/health span, we won’t shy away from “difficult indications” or innovative platforms which may have higher failure rates than average.

“As for the success rates, one of our focus areas is building out an innovative portfolio and valuation projection model that incorporates latest thinking and progress on success rates. There are numerous innovative groups applying machine learning to get nuanced data on success rates, and we are actively working to identify them and find ways to collaborate. We hope that success rates go up for every program and every company in the industry, not just us! And if we find that our strategy is helping improve our rates, we will happily share our learning even if that means we are bringing up everyone’s batting average.”

Look out for our interviews with James Peyer here and Daisy Robinton coming soon.

Image courtesy of Cambrian Biopharma
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Humanpeople raising £700k for AI preventative health platform

Digital preventative health platform combines blood, DNA and microbiome testing to power up your healthspan with highly personalised supplements. DISCLOSURE: Longevity.Technology (a brand of...

Apollo closes $180m for age-related disease innovations

Apollo Health Ventures fund will drive breakthrough innovations combating age-related diseases. Apollo Health Ventures has announced the final closing of its second venture fund to...

Aging in place: technologies to live long and independently

Our comprehensive market intelligence report provides a deep dive into the opportunities and challenges facing the aging in place industry – and explains why...

Longevity Science Summit: care of aging population talks continue

Our dive into Longevity Week's Science Summit continues... Last week, Longevity.Technology was lucky enough to attend Longevity Forum's Science Summit at Oxford's Oriel College, part...

Longevica raises $2.5 million for open research platform

$2.5m in funding to support longevity research platform and study to accelerate the discovery of life extension mechanisms, launching in 2022. Longevica, a life science...

    Subscribe to our newsletter